TIGIT and neoplasm: Anti-TIGIT antibodies have the potential to improve the efficacy of PM21-NK cell tumor immunity, and adoptive PM21-NK cells and anti-TIGIT antibodies should be explored in future preclinical studies and clinical trials as a combination therapy against lung tumors.